Faillie JL, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, Martínez-Zapata MJ, Huerta C, Castells X, Rottenkolber M, Schmiedl S, Sabaté M, Ballarín E, Ibáñez L.
A new risk of bias checklist applicable to randomized trials, observational studies and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events.
J Clin Epidemiol 2017;86:168-75.
https://doi.org/10.1016/j.jclinepi.2017.04.023
IF: 4,978
Ordi J, Sáez L, Pérez M, Vidal X, Mitjavila F, Castro A, Cuquet J, Ortiz V, Mauri M, Cortés J.
Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.
Ann Rheum Dis 2017:1-8.
http://dx.doi.org/10.1136/annrheumdis-2016-210882
IF: 12,811
Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MK, Day ChP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watking PB, Floratos A, Shen Y, Nelson MR, Urban TJ, and Daly AK, on behalf of International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.
Association of liver injury from specific drugs, or grups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study.
Gastroenterology 2017;152:1078-89.
IF: 18,392
Bonanno PV, Ermisch M, Godman B, Martin AP, Van Den Bergh J, Bezmelnitsyna L, Bucsics A, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogène E, Eriksson I, Fürst J, Gad M, Grei?i?té-Kuprijanov I, van der Graaff M, Gulbinovic J, Jones J, Joppi R, Kalaba M, Laius O, Langner I, Mardare I, Karkovic-Pekovic V, Magnusson E, Melien O, Meshkov DO, Petrova GI, Selke G, Sermet C, Simoens S, Schuurman A, Ramos R, Rodriguez J, Zara C, Zebedin-Brandi E, Haycox A.
Adaptive pathways: possible next steps for payers in preparation for their potential implementation.
Frontiers in Pharmacology 2017;8:1-13.Doi:10.3389/fphar.2017.00497.
IF: 4,400
Plessis L, Gómez A, García N, Cereza G, Figueras A.
Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia – a restraint to the potentiality for signal detection.
Eur J Clin Pharmacol 2017;73:751-58. Doi:10.1007/s00228-017-2223-5.
IF: 2,902
View all publications
